Acute Myeloid Leukemia: key endpoint results by drug

The key endpoints of Acute Myeloid Leukemia trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Acute Myeloid Leukemia page.

OS, median

OS, median in Acute Myeloid Leukemia: 16 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Durvalumab11.614.4 (Azacitidine)—n 42NCT02775903 Phase 2, secondary
Gilteritinib9.89.2 (AZA)—n 89NCT02752035 Phase 3, primary
Glasdegib17.320.4−3.1n 201NCT03416179 Phase 3, primary
Quizartinib31.915.1+16.8n 268NCT02668653 Phase 3, primary
Selinexor3.15.6 (Physician's Choice)—60 mg (Equivalent to 35 mg/m^2) · n 118NCT02088541 Phase 2, primary
Vyxeos9.66.0 (7+3)—n 153NCT01696084 Phase 3, primary
Atezolizumab5.8b——120 mg + 840 mg · n 3NCT03730012 Phase 1/2, secondary
Azacitidine10.4b——n 241NCT01074047 Phase 3, primary
Crenolanib7.8b——n 13NCT01657682 Phase 2, secondary
Daratumumab3.6b——n 16NCT02807558 Phase 2, secondary
Enasidenib6.5b——n 158NCT02577406 Phase 3, primary
Gemtuzumab Ozogamicin27.9b——n 138NCT00049517 Phase 3, secondary
Midostaurin6.2b——n 26NCT03092674 Phase 2/3, primary
Nivolumab6.2b——n 26NCT03092674 Phase 2/3, primary
Olutasidenib11.6b——n 153NCT02719574 Phase 1/2, secondary
Pembrolizumab42.2b——200 mg · n 12NCT02708641 Phase 2, secondary

Drugs checked with no result here: 45 not reported, 3 not posted, 18 trial running.

Complete remission

Complete remission in Acute Myeloid Leukemia: 11 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Gemtuzumab Ozogamicin69%68.6% (Ara-C+Daunomycin)—n 300NCT00085709 Phase 3, primary
Gilteritinib21.1%10.5% (Salvage Chemotherapy)—wk 24 · n 247NCT02421939 Phase 3, secondary
Selinexor5.1%0% (Physician's Choice)—60 mg (Equivalent to 35 mg/m^2) · n 118NCT02088541 Phase 2, secondary
Vyxeos48.8%48.8% (Cytarabine + Daunorubicin)—n 84NCT00788892 Phase 2, primary
Atezolizumab33.3%b——120 mg + 420 mg · n 3NCT03730012 Phase 1/2, secondary
Azacitidine13.3%b——400 mg + 75 mg · n 30NCT03941964 Phase 3, secondary
Enasidenib23.4%b——n 158NCT02577406 Phase 3, secondary
Pembrolizumab37.8%b——n 37NCT02768792 Phase 2, primary
Quizartinib2.6%b——60 mg · wk 156 · n 38NCT01565668 Phase 2, secondary
Tretinoin100%b——wk 208 · n 16NCT01404949 Phase 2, secondary
Venetoclax13.3%b——400 mg + 75 mg · n 30NCT03941964 Phase 3, secondary

Drugs checked with no result here: 49 not reported, 4 not posted, 18 trial running.

Event-free survival, median

Event-free survival, median in Acute Myeloid Leukemia: 14 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Azacitidine17.715.7 (Azacitidine)—20 mg/m^2 + 75 mg/m^2 · n 227NCT03268954 Phase 3, primary
Gilteritinib0.00.0 (AZA)—n 89NCT02752035 Phase 3, secondary
Ivosidenib0.00.0±0n 72NCT03173248 Phase 3, primary
Midostaurin6.05.9+0.1n 250NCT03512197 Phase 3, primary
Quizartinib0.00.7−0.7n 268NCT02668653 Phase 3, secondary
Venetoclax7.711.2 (Venetoclax + Azacitidine)—20 mg/m^2 + 100/200/400 mg + 75 mg/m^2 · n 83NCT04266795 Phase 2, primary
Vyxeos2.51.3 (7+3)—n 153NCT01696084 Phase 3, secondary
Atezolizumab5.8b——120 mg + 420 mg · n 3NCT03730012 Phase 1/2, secondary
Daratumumab1.2b——n 16NCT02807558 Phase 2, secondary
Enasidenib4.9b——n 158NCT02577406 Phase 3, secondary
Nivolumab3.6b——n 26NCT03092674 Phase 2/3, secondary
Olutasidenib5.5b——n 153NCT02719574 Phase 1/2, secondary
Selinexor4.3b——60 mg flat dose · n 15NCT02249091 Phase 2, secondary
Tretinoin1.4b——6 mg/kg/day + 45 mg/m^2/day · n 4NCT02842827 Phase 1/2, primary

Drugs checked with no result here: 48 not reported, 17 trial running, 3 not posted.

Duration of response, median

Duration of response, median in Acute Myeloid Leukemia: 11 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Azacitidine17.118.3 (Azacitidine)—20 mg/m^2 + 75 mg/m^2 · n 64NCT03268954 Phase 3, secondary
Durvalumab5.712 (Azacitidine)—n 20NCT02775903 Phase 2, secondary
Gilteritinib14.81.8 (Salvage Chemotherapy)—n 52NCT02421939 Phase 3, secondary
Selinexor6.74.9 (Physician's Choice)—60 mg (Equivalent to 35 mg/m^2) · n 16NCT02088541 Phase 2, secondary
Vyxeos6.96.1 (7+3)—n 153NCT01696084 Phase 3, secondary
Brentuximab Vedotin2.9b——n 7NCT01461538 Phase 2, secondary
Enasidenib7.4b——n 64NCT02577406 Phase 3, secondary
Midostaurin0.9b——200 mg/day · n 13NCT00045942 Phase 1/2, secondary
Olutasidenib14.8b——n 75NCT02719574 Phase 1/2, secondary
Pembrolizumab12.0b——n 2NCT02981914 Phase 1, secondary
Quizartinib3.6b——n 83NCT00989261 Phase 2, secondary

Drugs checked with no result here: 47 not reported, 6 not posted, 18 trial running.

  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 82 approved or late-stage drugs with a featured trial in Acute Myeloid Leukemia were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.